Content validity of symptom-based measures for diabetic, chemotherapy, and HIV peripheral neuropathy

Jennifer S. Gewandter, Laurie Burke, Guido Cavaletti, Robert H. Dworkin, Christopher Gibbons, Tony D. Gover, David N. Herrmann, Justin C. Mcarthur, Michael P. McDermott, Bob A. Rappaport, Bryce B. Reeve, James W. Russell, A. Gordon Smith, Shannon M. Smith, Dennis C. Turk, Aaron I. Vinik, Roy Freeman

Research output: Contribution to journalArticle

  • 1 Citations

Abstract

Introduction: No treatments for axonal peripheral neuropathy are approved by the United States Food and Drug Administration (FDA). Although patient- and clinician-reported outcomes are central to evaluating neuropathy symptoms, they can be difficult to assess accurately. The inability to identify efficacious treatments for peripheral neuropathies could be due to invalid or inadequate outcome measures. Methods: This systematic review examined the content validity of symptom-based measures of diabetic peripheral neuropathy, HIV neuropathy, and chemotherapy-induced peripheral neuropathy. Results: Use of all FDA-recommended methods to establish content validity was only reported for 2 of 18 measures. Multiple sensory and motor symptoms were included in measures for all 3 conditions; these included numbness, tingling, pain, allodynia, difficulty walking, and cramping. Autonomic symptoms were less frequently included. Conclusions: Given significant overlap in symptoms between neuropathy etiologies, a measure with content validity for multiple neuropathies with supplemental disease-specific modules could be of great value in the development of disease-modifying treatments for peripheral neuropathies. Muscle Nerve 55: 366–372, 2017.

LanguageEnglish (US)
Pages366-372
Number of pages7
JournalMuscle and Nerve
Volume55
Issue number3
DOIs
StatePublished - Mar 1 2017

Fingerprint

Peripheral Nervous System Diseases
HIV
Drug Therapy
United States Food and Drug Administration
Mobility Limitation
Hypesthesia
Diabetic Neuropathies
Hyperalgesia
Therapeutics
Outcome Assessment (Health Care)
Pain
Muscles

Keywords

  • content validity
  • drug development
  • measure development
  • outcome measures
  • peripheral neuropathy
  • systematic review

ASJC Scopus subject areas

  • Physiology
  • Clinical Neurology
  • Cellular and Molecular Neuroscience
  • Physiology (medical)

Cite this

Gewandter, J. S., Burke, L., Cavaletti, G., Dworkin, R. H., Gibbons, C., Gover, T. D., ... Freeman, R. (2017). Content validity of symptom-based measures for diabetic, chemotherapy, and HIV peripheral neuropathy. Muscle and Nerve, 55(3), 366-372. DOI: 10.1002/mus.25264

Content validity of symptom-based measures for diabetic, chemotherapy, and HIV peripheral neuropathy. / Gewandter, Jennifer S.; Burke, Laurie; Cavaletti, Guido; Dworkin, Robert H.; Gibbons, Christopher; Gover, Tony D.; Herrmann, David N.; Mcarthur, Justin C.; McDermott, Michael P.; Rappaport, Bob A.; Reeve, Bryce B.; Russell, James W.; Smith, A. Gordon; Smith, Shannon M.; Turk, Dennis C.; Vinik, Aaron I.; Freeman, Roy.

In: Muscle and Nerve, Vol. 55, No. 3, 01.03.2017, p. 366-372.

Research output: Contribution to journalArticle

Gewandter, JS, Burke, L, Cavaletti, G, Dworkin, RH, Gibbons, C, Gover, TD, Herrmann, DN, Mcarthur, JC, McDermott, MP, Rappaport, BA, Reeve, BB, Russell, JW, Smith, AG, Smith, SM, Turk, DC, Vinik, AI & Freeman, R 2017, 'Content validity of symptom-based measures for diabetic, chemotherapy, and HIV peripheral neuropathy' Muscle and Nerve, vol 55, no. 3, pp. 366-372. DOI: 10.1002/mus.25264
Gewandter JS, Burke L, Cavaletti G, Dworkin RH, Gibbons C, Gover TD et al. Content validity of symptom-based measures for diabetic, chemotherapy, and HIV peripheral neuropathy. Muscle and Nerve. 2017 Mar 1;55(3):366-372. Available from, DOI: 10.1002/mus.25264
Gewandter, Jennifer S. ; Burke, Laurie ; Cavaletti, Guido ; Dworkin, Robert H. ; Gibbons, Christopher ; Gover, Tony D. ; Herrmann, David N. ; Mcarthur, Justin C. ; McDermott, Michael P. ; Rappaport, Bob A. ; Reeve, Bryce B. ; Russell, James W. ; Smith, A. Gordon ; Smith, Shannon M. ; Turk, Dennis C. ; Vinik, Aaron I. ; Freeman, Roy. / Content validity of symptom-based measures for diabetic, chemotherapy, and HIV peripheral neuropathy. In: Muscle and Nerve. 2017 ; Vol. 55, No. 3. pp. 366-372
@article{a67d8499974f4d62b7f8f6e9fa917a01,
title = "Content validity of symptom-based measures for diabetic, chemotherapy, and HIV peripheral neuropathy",
abstract = "Introduction: No treatments for axonal peripheral neuropathy are approved by the United States Food and Drug Administration (FDA). Although patient- and clinician-reported outcomes are central to evaluating neuropathy symptoms, they can be difficult to assess accurately. The inability to identify efficacious treatments for peripheral neuropathies could be due to invalid or inadequate outcome measures. Methods: This systematic review examined the content validity of symptom-based measures of diabetic peripheral neuropathy, HIV neuropathy, and chemotherapy-induced peripheral neuropathy. Results: Use of all FDA-recommended methods to establish content validity was only reported for 2 of 18 measures. Multiple sensory and motor symptoms were included in measures for all 3 conditions; these included numbness, tingling, pain, allodynia, difficulty walking, and cramping. Autonomic symptoms were less frequently included. Conclusions: Given significant overlap in symptoms between neuropathy etiologies, a measure with content validity for multiple neuropathies with supplemental disease-specific modules could be of great value in the development of disease-modifying treatments for peripheral neuropathies. Muscle Nerve 55: 366–372, 2017.",
keywords = "content validity, drug development, measure development, outcome measures, peripheral neuropathy, systematic review",
author = "Gewandter, {Jennifer S.} and Laurie Burke and Guido Cavaletti and Dworkin, {Robert H.} and Christopher Gibbons and Gover, {Tony D.} and Herrmann, {David N.} and Mcarthur, {Justin C.} and McDermott, {Michael P.} and Rappaport, {Bob A.} and Reeve, {Bryce B.} and Russell, {James W.} and Smith, {A. Gordon} and Smith, {Shannon M.} and Turk, {Dennis C.} and Vinik, {Aaron I.} and Roy Freeman",
year = "2017",
month = "3",
day = "1",
doi = "10.1002/mus.25264",
language = "English (US)",
volume = "55",
pages = "366--372",
journal = "Muscle and Nerve",
issn = "0148-639X",
publisher = "John Wiley and Sons Inc.",
number = "3",

}

TY - JOUR

T1 - Content validity of symptom-based measures for diabetic, chemotherapy, and HIV peripheral neuropathy

AU - Gewandter,Jennifer S.

AU - Burke,Laurie

AU - Cavaletti,Guido

AU - Dworkin,Robert H.

AU - Gibbons,Christopher

AU - Gover,Tony D.

AU - Herrmann,David N.

AU - Mcarthur,Justin C.

AU - McDermott,Michael P.

AU - Rappaport,Bob A.

AU - Reeve,Bryce B.

AU - Russell,James W.

AU - Smith,A. Gordon

AU - Smith,Shannon M.

AU - Turk,Dennis C.

AU - Vinik,Aaron I.

AU - Freeman,Roy

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Introduction: No treatments for axonal peripheral neuropathy are approved by the United States Food and Drug Administration (FDA). Although patient- and clinician-reported outcomes are central to evaluating neuropathy symptoms, they can be difficult to assess accurately. The inability to identify efficacious treatments for peripheral neuropathies could be due to invalid or inadequate outcome measures. Methods: This systematic review examined the content validity of symptom-based measures of diabetic peripheral neuropathy, HIV neuropathy, and chemotherapy-induced peripheral neuropathy. Results: Use of all FDA-recommended methods to establish content validity was only reported for 2 of 18 measures. Multiple sensory and motor symptoms were included in measures for all 3 conditions; these included numbness, tingling, pain, allodynia, difficulty walking, and cramping. Autonomic symptoms were less frequently included. Conclusions: Given significant overlap in symptoms between neuropathy etiologies, a measure with content validity for multiple neuropathies with supplemental disease-specific modules could be of great value in the development of disease-modifying treatments for peripheral neuropathies. Muscle Nerve 55: 366–372, 2017.

AB - Introduction: No treatments for axonal peripheral neuropathy are approved by the United States Food and Drug Administration (FDA). Although patient- and clinician-reported outcomes are central to evaluating neuropathy symptoms, they can be difficult to assess accurately. The inability to identify efficacious treatments for peripheral neuropathies could be due to invalid or inadequate outcome measures. Methods: This systematic review examined the content validity of symptom-based measures of diabetic peripheral neuropathy, HIV neuropathy, and chemotherapy-induced peripheral neuropathy. Results: Use of all FDA-recommended methods to establish content validity was only reported for 2 of 18 measures. Multiple sensory and motor symptoms were included in measures for all 3 conditions; these included numbness, tingling, pain, allodynia, difficulty walking, and cramping. Autonomic symptoms were less frequently included. Conclusions: Given significant overlap in symptoms between neuropathy etiologies, a measure with content validity for multiple neuropathies with supplemental disease-specific modules could be of great value in the development of disease-modifying treatments for peripheral neuropathies. Muscle Nerve 55: 366–372, 2017.

KW - content validity

KW - drug development

KW - measure development

KW - outcome measures

KW - peripheral neuropathy

KW - systematic review

UR - http://www.scopus.com/inward/record.url?scp=85007370291&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85007370291&partnerID=8YFLogxK

U2 - 10.1002/mus.25264

DO - 10.1002/mus.25264

M3 - Article

VL - 55

SP - 366

EP - 372

JO - Muscle and Nerve

T2 - Muscle and Nerve

JF - Muscle and Nerve

SN - 0148-639X

IS - 3

ER -